Invention Grant
- Patent Title: ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolism
-
Application No.: US17293356Application Date: 2019-11-13
-
Publication No.: US12024708B2Publication Date: 2024-07-02
- Inventor: Frank Jaschinski , Anne Sadewasser , Sven Michel
- Applicant: Lipigon Pharmaceuticals AB
- Applicant Address: SE Umeå
- Assignee: LIPIGON PHARMACEUTICALS AB
- Current Assignee: LIPIGON PHARMACEUTICALS AB
- Current Assignee Address: SE Umeå
- Agency: Knobbe, Martens, Olson & Bear, LLP
- Priority: EP 206087 2018.11.13
- International Application: PCT/EP2019/081161 2019.11.13
- International Announcement: WO2020/099478A 2020.05.22
- Date entered country: 2021-05-12
- Main IPC: C07H21/04
- IPC: C07H21/04 ; C12N15/113
Abstract:
An ANGPTL4 inhibitor consisting of an oligonucleotide has 12 to 22 nucleotides. At least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of human and/or mouse ANGPTL4 and inhibits the expression of ANGPTL4. Also disclosed herein is a pharmaceutical composition of the ANGPTL4 inhibitor and a pharmaceutically acceptable carrier, excipient, diluent, or a combination thereof.
Public/Granted literature
- US20220010311A1 ANGPTL4 OLIGONUCLEOTIDES INFLUENCING THE REGULATION OF THE FATTY ACID METABOLISM Public/Granted day:2022-01-13
Information query
